Summaries & Highlights
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Preferred Treatment Regimens for Rare GU Malignancies
FEATURING
Nicholas Simon
- April 12, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: SOLAR & SATURN Clinical Trials - Comparing the Progression of De Novo vs. Recurrent PSMA-Defined Oligo-M1 Prostate Cancer Following Systemic Therapy & Tumor-Directed Therapy
FEATURING
Amar Kishan
- April 12, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Immunogenomic Determinants of Exceptional Response to ICI in RCC - Data From CheckMate 214 and JAVELIN Renal 101
FEATURING
Renee Maria Saliby
- 28 views
- March 19, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: The Future of Biomarkers in RCC
FEATURING
Samra Turajlic
- 38 views
- March 10, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Striving Toward New Frontiers in Clear Cell Kidney Cancer - Insights From Key Trials
FEATURING
Tian Zhang
- 105 views
- March 4, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Advances in Metastatic Prostate Cancer Treatment - AI, Genomics, Radioligand Therapy, and Drug Comparisons
FEATURING
Pedro Barata
- 122 views
- March 4, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: The Changing World of NMIBC
FEATURING
Bogdana Schmidt
- 61 views
- February 26, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Biomarkers in RCC - Current State and Future Potential
FEATURING
Simpa Salami
- 142 views
- February 26, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: The Promise of ADCs in Combination Therapies for Advanced/Metastatic Urothelial Cancer
FEATURING
Terence Friedlander
- 150 views
- February 24, 2025
- 1
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Retreatment With EV/Pembro or ICI After Prior ICI in Advanced Urothelial Cancer - UNITE & KEYNOTE Analysis
FEATURING
Vadim Koshkin
- 148 views
- February 24, 2025
- 1
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Adjuvant Therapy in RCC - A Practical Guide
FEATURING
Laurence Albiges
- 76 views
- February 24, 2025
- 2
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Perioperative Strategies in MIBC - Key Trial Insights Including CheckMate 274, NIAGARA, and RETAIN-2
FEATURING
Elizabeth R. Plimack
- 243 views
- February 20, 2025
Bladder & Urothelial Cancer
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Perioperative Sacituzumab Govitecan + Zimberelimab + Domvanalimab in Cisplatin Ineligible MIBC Patients - PRISMA-1 Study
FEATURING
Ignacio Durán
- 3 views
- April 9, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Active Surveillance vs. Definitive Local Therapy for Bladder Cancer Patients Showing cCR Following Neoadjuvant Treatment
FEATURING
Marie-Pier St-Laurent
- 24 views
- March 25, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Targeting Bladder Cancer With Antibody-Drug Conjugates
FEATURING
Maria Jiang
- 44 views
- March 11, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: The Changing World of NMIBC
FEATURING
Bogdana Schmidt
- 61 views
- February 26, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Adjuvant Nivo vs. Placebo in High-Risk MIUC - Updated Efficacy and OS Data in MIBC From CheckMate 274
FEATURING
Matthew Milowsky
- 84 views
- February 26, 2025
- 1
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Neoadjuvant Durvalumab + Chemo in Operable High-Risk UTUC - iNDUCT Trial
FEATURING
Nadine Houede
- 43 views
- February 25, 2025
- 1
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: The Promise of ADCs in Combination Therapies for Advanced/Metastatic Urothelial Cancer
FEATURING
Terence Friedlander
- 150 views
- February 24, 2025
- 1
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Retreatment With EV/Pembro or ICI After Prior ICI in Advanced Urothelial Cancer - UNITE & KEYNOTE Analysis
FEATURING
Vadim Koshkin
- 148 views
- February 24, 2025
- 1
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: The Role of ctDNA in Improving Clinical Staging for Upper Tract Urothelial Carcinoma
FEATURING
Roger Li
- 21 views
- February 24, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Perioperative Strategies in MIBC - Key Trial Insights Including CheckMate 274, NIAGARA, and RETAIN-2
FEATURING
Elizabeth R. Plimack
- 243 views
- February 20, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: ABLE-32 Trial - Evaluating Nadoferogene Firadenovec (NADO) for Recurrence Prevention in Intermediate-Risk NMIBC
FEATURING
Neal Shore
- 119 views
- February 19, 2025
- 2
Renal Cell Carcinoma
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Survival of Patients With mRCC With or Without Brain Metastases
FEATURING
Michael Hurwitz
- 27 views
- April 2, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Updated Results of the TIDE-A Study Evaluating Avelumab + Intermittent Axitinib in Previously Untreated Patients With mRCC
FEATURING
Chiara Ciccarese
- 20 views
- March 30, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Immunogenomic Determinants of Exceptional Response to ICI in RCC - Data From CheckMate 214 and JAVELIN Renal 101
FEATURING
Renee Maria Saliby
- 28 views
- March 19, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: The Future of Biomarkers in RCC
FEATURING
Samra Turajlic
- 38 views
- March 10, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Association Between PD-1 Expression on Regulatory T Cells and Resistance to 1L Nivo in Advanced ccRCC - HCRN GU16-260 Trial
FEATURING
Razan Mohanna
- 4 views
- March 7, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Efficacy Outcomes With Belzutifan vs. Everolimus by Baseline Disease Characteristics and Burden Subgroups - LITESPARK-005 Study
FEATURING
Guillermo de Velasco
- 33 views
- March 4, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Striving Toward New Frontiers in Clear Cell Kidney Cancer - Insights From Key Trials
FEATURING
Tian Zhang
- 105 views
- March 4, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in mRCC - BOOST-RCC Study
FEATURING
Tian Zhang
- 13 views
- March 4, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Final OS and ctDNA Data for Savolitinib + Durvalumab in Advanced Papillary Renal Cancer - CALYPSO Trial
FEATURING
Francesca Jackson-Spence
- 11 views
- February 27, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Biomarkers in RCC - Current State and Future Potential
FEATURING
Simpa Salami
- 142 views
- February 26, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Efficacy and Safety of Nivo/Ipi in Metastatic Variant Histology RCC - A Retrospective Analysis From MD Anderson
FEATURING
Mohammad Jad Moussa
- 78 views
- February 25, 2025
- 2
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Adjuvant Therapy in RCC - A Practical Guide
FEATURING
Laurence Albiges
- 76 views
- February 24, 2025
- 2
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Cytoreductive Nephrectomy in mRCC - Perioperative Risk Characteristics in the Contemporary Era
FEATURING
Shawn Dason
- 19 views
- February 21, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Cabozantinib + Nivo + Ipi in 1L aRCC - Final Results of COSMIC-313
FEATURING
Laurence Albiges
- 59 views
- February 20, 2025
- 2
Prostate Cancer
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: SOLAR & SATURN Clinical Trials - Comparing the Progression of De Novo vs. Recurrent PSMA-Defined Oligo-M1 Prostate Cancer Following Systemic Therapy & Tumor-Directed Therapy
FEATURING
Amar Kishan
- April 12, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO GU 2025 Insights: TRITON3 Final OS and Safety - Rucaparib vs. Docetaxel or Second-Generation ARPI in mCRPC
FEATURING
Alan Bryce
- 1 view
- April 11, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Initial Biopsy Results Screening for Inherited Risk of Developing Aggressive Prostate Cancer - PATROL Study
FEATURING
Daniel Lee
- 1 view
- April 9, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Choice of Androgen Receptor Pathway Inhibitors (ARPi) by Disease Volume and Timing of Metastases in mHSPC
FEATURING
Syed Arsalan Ahmed Naqvi
- 3 views
- April 9, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Can MRI Accurately Replace Confirmatory Biopsy for Prostate Cancer Patients on Active Surveillance?
FEATURING
Matthew Cooperberg
- 22 views
- April 2, 2025
- 1
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Age-Related Outcomes of Darolutamide + ADT and Docetaxel in mHSPC: Subgroup Analysis From ARASENS
FEATURING
Joan Carles
- 11 views
- March 27, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: HSD3B1 and OS in Metastatic and Non-Metastatic Prostate Cancer Starting ADT With ENZ or AAP - STAMPEDE Trial
FEATURING
Nima Sharifi
- 10 views
- March 12, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Impact of BRCA Status in mCRPC Patients Undergoing Abiraterone +/- SBRT - ARTO Trial
FEATURING
Giulio Francolini
- 3 views
- March 11, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Adrenal Androgens and OS in Men With mCRPC Treated With ENZ or ENZ/AAP - Alliance Trial
FEATURING
Nima Sharifi
- 13 views
- March 7, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Neoadjuvant Intra-Arterial 177Lu-PSMA-617 in High-Risk Localized or Locally Advanced Prostate Cancer - LUPUS Trial
FEATURING
Claudia Kesch
- 6 views
- March 7, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Efficacy of 177Lu-PSMA-617 +/- ARPIs for the Treatment of mCRPC - VISION Secondary Analysis
FEATURING
Omid Yazdanpanah
- 105 views
- March 6, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: AI-Derived Tumor Volume From Baseline MRI and Postprostatectomy Outcomes Following Neoadjuvant Hormonal Therapy for High-Risk Prostate Cancer
FEATURING
David Yang
- 7 views
- March 6, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Advances in Metastatic Prostate Cancer Treatment - AI, Genomics, Radioligand Therapy, and Drug Comparisons
FEATURING
Pedro Barata
- 122 views
- March 4, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: mCRPC Survival Outcomes With 177Lu-PSMA-617 Based on Line of Therapy
FEATURING
Nicolas Sayegh
- 131 views
- February 25, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: The Influence of Boosting Gut Health and Phytochemical-Rich Foods in Men With Prostate Cancer
FEATURING
Robert Thomas
- 231 views
- February 19, 2025
- 6
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Final Outcomes of the ARNEO Trial - Neoadjuvant Degarelix +/- Apalutamide Before Radical Prostatectomy in High-Risk Prostate Cancer
FEATURING
Alexander Giesen
- 35 views
- February 18, 2025